FINANCIAL STATEMENTS 111 4 EARNINgS pER $0.25 oRdINARy SHARE 2008 2007 2006 Profit for the financial year attributable to equity holders $m 6,101 5,595 6,043 Basic earnings per Ordinary Share $4.20 $3.74 $3.86 Diluted earnings per Ordinary Share $4.20 $3.73 $3.85 Weighted average number of Ordinary Shares in issue for basic earnings millions 1,453 1,495 1,564 Dilutive impact of share options outstanding millions 3 6 Diluted weighted average number of Ordinary Shares in issue millions 1,453 1,498 1,570 There are no options, warrants or rights outstanding in respect of unissued shares except for employee share option schemes.
The number of options outstanding and the weighted average exercise price of these options is shown in Note 24.
The earnings figures used in the calculations above are post-tax and are unchanged for diluted earnings per Ordinary Share.
5 SEgmENT INFoRmATIoN The Groups activities are in one business segment, pharmaceuticals.
There are no other significant classes of business, either singularly or in aggregate.
gEogRApHIC AREAS The tables below show information by geographic area and, for revenue and property, plant and equipment, material countries.
The figures show the revenue, operating profit and profit before tax made by companies located in that area country, together with segment assets, segment assets acquired, net operating assets and property, plant and equipment owned by the same companies: export sales and the related profit are included in the area country from which those sales were made.
Intra-Group pricing is determined on an arms length basis.
ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008
